| Net income (loss) attributable to Nabors | |
| Depreciation and amortization | 657.54M |
| Depletion and other exploratory expenses | |
| Deferred income tax expense (benefit) | -168.41M |
| Deferred financing costs amortization | |
| Pension liability amortization and adjustments | |
| Discount amortization on long-term debt | |
| Amortization of loss on hedges | |
| Losses (gains) on long-lived assets, net | |
| Losses (gains) on investments, net | |
| Losses (gains) on debt retirement, net | |
| Losses (gains) on derivative instruments | |
| Share-based compensation | 24.07M |
| Foreign currency transaction losses (gains), net | 5.92M |
| Equity in (earnings) losses of unconsolidated affiliates, net of dividends | 221.92M |
| Accounts receivable | 255.46M |
| Inventory | 14.66M |
| Other current assets | 30.19M |
| Other long-term assets | |
| Trade accounts payable and accrued liabilities | -187.77M |
| Income taxes payable | -22.5M |
| Other long-term liabilities | |
| Net cash provided by operating activities | 404.77M |
| Purchases of investments | -24K |
| Sales and maturities of investments | 643K |
| Investment in unconsolidated affiliates | 0 |
| Distribution of proceeds from asset sales from unconsolidated affiliates | |
| Capital expenditures | -284.95M |
| Proceeds from sales of assets and insurance claims | |
| Net cash used for investing activities | -257.75M |
| Increase (decrease) in cash overdrafts | 5K |
| Proceeds from issuance of common shares | 562K |
| Proceeds from revolving credit facilities | 560M |
| Debt issuance costs | |
| Reduction in long-term debt | -492.63M |
| Repurchase of equity component of convertible debt | |
| Settlement of call options and warrants, net | |
| Purchase of restricted stock | |
| Tax benefit related to share-based awards | |
| Net cash used for financing activities | -223.37M |
| Effect of exchange rate changes on cash and cash equivalents | -1.13M |
| Net (decrease) increase in cash and cash equivalents | -77.49M |
| Cash and cash equivalents, beginning of period | 254.53M |
| Cash and cash equivalents, end of period | 177.04M |